From the Journals

Late toxicities with PARP inhibitor plus RT in inflammatory breast cancer


 

FROM JOURNAL OF CLINICAL ONCOLOGY


The investigators noted that, at year 3, severe fibrosis in the treatment field was seen in 6 of the 15 surviving patients. Of the six patients, two also had grade 3 skin induration, and two had grade 3 lymphedema.

“Although some of the late adverse events we observed might have occurred even in the absence of the investigational agent and with standard therapy, severe late toxicity is relatively uncommon with standard therapy alone, so we believe that a cautious approach is prudent,” Dr. Jagsi and associates wrote.

The study was supported by the Translational Breast Cancer Research Consortium, Breast Cancer Research Foundation, University of Michigan Comprehensive Cancer Center, and Michigan Institute for Clinical and Health Research. Dr. Jagsi reported institutional research support from AbbVie, which donated the veliparib used in the study.

SOURCE: Jagsi R et al. J Clin Oncol. 2018 Mar 20. doi: 10.1200/JCO.2017.77.2665

Pages

Recommended Reading

Measurement of physical activity and sedentary behavior in breast cancer survivors
MDedge Hematology and Oncology
Breast cancer deaths projected for 2018
MDedge Hematology and Oncology
FDA approves abemaciclib plus aromatase inhibitor as initial therapy
MDedge Hematology and Oncology
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge Hematology and Oncology
Breast cancer care delayed when patients have high deductibles
MDedge Hematology and Oncology
Age at time of breast cancer diagnosis differs by race/ethnicity
MDedge Hematology and Oncology
CECCY: Carvedilol didn’t curb cardiotoxicity in breast cancer patients
MDedge Hematology and Oncology
Gaps exist in receipt of clinically indicated genetic counseling after breast cancer diagnosis
MDedge Hematology and Oncology
Fulvestrant plus neratinib reversed treatment-acquired HER2 mutations in metastatic ER+ breast cancer
MDedge Hematology and Oncology
Accelerated breast irradiation advocated by ASTRO guideline
MDedge Hematology and Oncology